PassPort Technologies, Inc. Initiated US Phase I Clinical Trial of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine

SAN DIEGO, Feb. 23, 2024 /PRNewswire/ — PassPort Technologies, Inc. (PPTI), based in San Diego, initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort® platform technology. The study objectives are to evaluate…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks